Biote's Procedure Growth Recovery Is the Real Test After the Recall

The quarter was hit by the recall, but the second-half recovery is the real question

Biote's first-quarter miss is the obvious headline, but the more important issue is whether the company is still on a credible recovery path or whether the recall exposed a deeper problem.

What changed, in plain English

Management still says the core story is intact. It expects procedure growth to return in the second half of 2026 and maintains a path to revenue above $190 million. Those targets matter because they shift the focus from one-quarter weakness to whether the business can restart procedure momentum later this year.

That is easier to say than to prove. The first quarter still reflected real disruption from the recall, and Biote has said performance was driven primarily by a $1.7 million revenue headwind. For a company whose long-term case depends on practitioner scheduling and repeat visits, supply reliability matters just as much as guidance.

Why the timing matters now

If the setback was mostly temporary, the second half of 2026 should begin to show better conversion from the company's trained-practitioner base and its expanded commercial team. If that does not start to show up, investors have reason to question whether the recall was merely a temporary disruption or a sign of weaker underlying demand.

The underlying activity mostly holds up, but procedure growth is still missing

The cleanest way to assess Biote right now is to separate what is already working from what still needs to happen.

What the first quarter confirmed

Start with the clearest proof of demand. Supplement revenue rose 19.1% to $11.0 million in the first quarter. That is the strongest evidence the company has that consumer demand is still there. Management's outlook for more modest full-year supplement growth also feels more measured than the Q1 breakout.

The commercial buildout is another positive signal. Biote grew from just over 90 representatives at the end of 2025 to about 120 personnel, after adding more than 25 new hires in the first quarter alone. A larger field team should help with practitioner follow-through once supply stabilizes.

Training is the next link. Biote says it trained more than 200 practitioners in Q1, and management views that as a leading indicator because newly trained clinicians usually take about six months to start contributing meaningfully. In practical terms, that means current training activity should support later revenue only if those practitioners begin scheduling insertions and retaining patients.

Where the bear case gets stronger

The bear case is more credible than a simple "recall equals damage" framing would suggest. The company pulled lots linked to a potential presence of metal particulate matter, expects about $1.0 million of additional recall-related costs in 2026, and said the episode became a significant operational distraction that shifted the sales force toward account servicing and inventory allocation instead of new growth.

That makes the current setup a live test of execution, not just sentiment. Headcount and training numbers are useful leading indicators, but they do not matter much unless they translate into practitioner scheduling, repeat visits, and procedure growth.

What would confirm the recovery - and what would break it

The next few quarters should make clear whether Biote is rebuilding demand or simply managing around the recall.

The scorecard for investors

Management has tied the recovery to the second half of 2026, so the next two earnings reports are the key reality checks. If procedure momentum still has not appeared once that window opens, the turnaround story becomes harder to support.

Supply is the first place to look. Biote says the second production shift should restore full supply continuity by end-Q2, and the sales team is near the targeted level of about 120 representatives. If both of those hold, the company should be in a better position to convert trained practitioners into actual procedure growth.

What would prove management wrong

The recovery case weakens materially if supply is mostly back by end-Q2, the sales force remains near target, and procedure growth still does not return in the second half. In that scenario, the recall would look less like a temporary interruption and more like a symptom of softer demand.

For now, the story looks more like a watchlist case than a confirmed turnaround. The best way to think about Biote is as a business whose later-2026 targets remain plausible, but not yet proven.